<DOC>
	<DOCNO>NCT00918827</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue laboratory patient cancer undergone surgery chemotherapy may help doctor predict well patient respond treatment . PURPOSE : This research study look tumor sample patient stage III colon cancer undergone surgery chemotherapy .</brief_summary>
	<brief_title>Study Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Identify predictive factor efficacy safety adjuvant chemotherapy comprise fluorouracil-based regimen patient stage III colon cancer . - Investigate possibility `` personalized treatment '' adjuvant chemotherapy base predictive factor identify . OUTLINE : Patients ' tumor tissue sample collect protein expression level thymidine phosphorylase ( TP ) , dihydropyrimidine dehydrogenase ( DPD ) , VEGF , EGFR , mRNA-expression level TP , DPD , thymidylate synthase ( TS ) , orotate phosphoribosyl transferase ( OPRT ) ELISA , Human Duo Set , RT-PCR assay . Patients ' enzyme expression level compare clinical data .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>&lt; Inclusion criterion &gt; Pathologically confirm stage III colon adenocarcinoma Curatively resect ( R0 ) Patients schedule treatment fluorouracilbased postoperative adjuvant chemotherapy Provided write informed consent &lt; Exclusion criterion &gt; Synchronous metachronous multiple cancer Contraindications fluorouracilbased chemotherapy Patients initiate neoadjuvant chemotherapy radiotherapy prior participate study Ineligible patient accord investigator 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage III colon cancer</keyword>
</DOC>